WO2013179300A2 - A process for the preparation of vildagliptin and its intermediate thereof - Google Patents

A process for the preparation of vildagliptin and its intermediate thereof Download PDF

Info

Publication number
WO2013179300A2
WO2013179300A2 PCT/IN2013/000296 IN2013000296W WO2013179300A2 WO 2013179300 A2 WO2013179300 A2 WO 2013179300A2 IN 2013000296 W IN2013000296 W IN 2013000296W WO 2013179300 A2 WO2013179300 A2 WO 2013179300A2
Authority
WO
WIPO (PCT)
Prior art keywords
vildagliptin
acid
formula
solution
solvent
Prior art date
Application number
PCT/IN2013/000296
Other languages
English (en)
French (fr)
Other versions
WO2013179300A3 (en
Inventor
Vijayavitthal MATHAD VIJAYAVITTHAL THIPPANNACHAR
Nilesh PATIL NILESH SUDHIR
Pavankumar SOLANKI PAVANKUMAR VRAJLAL
Sharad IPPAR SHARAD SUBHASH
Mahendra BODAKE MAHENDRA BHAGIRATH
Rajesh TALLA RAJESH
Anil MALI ANIL CHATURLAL
Original Assignee
Megafine Pharma (P) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Megafine Pharma (P) Ltd. filed Critical Megafine Pharma (P) Ltd.
Publication of WO2013179300A2 publication Critical patent/WO2013179300A2/en
Publication of WO2013179300A3 publication Critical patent/WO2013179300A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • the present invention relates to a process for the preparation of (2S)-1- ⁇ [(3- hydroxytricyclo [3.3.1.1 (3,7)dec-1-yl)amino]-2-pyrrolidine carbonitrile, vildagliptin of formula (I) and its intermediates.
  • the present invention also relates to a process for purification of vildagliptin; wherein the said process substantially eliminates the impurities.
  • the present invention also relates to novel co-precipitate of amorphous form of vildagliptin of formula (I) with a pharmaceutically acceptable carrier and the process for the preparation thereof.
  • Vildagliptin chemically known as (2S)-1- ⁇ [(3-hydroxytricyclo [3.3.1.1(3,7)dec- 1-yl)amino]-2-pyrrolidine carbonitrile is a dipeptidyl peptidase-IV (DPP-IV) inhibitor, used effectively for treatment of non-insulin-dependent diabetes mellitus.
  • DPP-IV dipeptidyl peptidase-IV
  • USO63 discloses the process for preparation of vildagliptin of formula (I) wherein, 1-aminoadamantane-3-ol of formula (IV) is reacted with 1- chloroacetyl-(S)-2-cyanopyrrolidine of formula (V) in tetrahydrofuran or dichloromethane in the presence of potassium carbonate to yield vildagliptin of formula (I).
  • the compound of formula (I) is further purified by column chromatography.
  • the synthetic compounds can contain impurities resulting from their synthesis or degradation. These impurities can be un-reacted starting materials, by-products of the reaction, products of side reaction, or degradation products. Impurities in active pharmaceutical ingredient (API) are undesirable and might be harmful.
  • the regulatory authorities worldwide require the drug manufacturer to isolate, identify and characterize the impurities in their product. Furthermore, the manufacturers are required to control the levels of these impurities in the final drug compound obtained by manufacturing process and ensure that the impurity is present in the lowest possible levels, even if structural determination is not possible.
  • US 7375238 disclose the novel process for the preparation of pure vildagliptin using mixtures of solvents. This patent also exemplifies the purification of vildagliptin using methyl ethyl ketone as solvent.
  • PCT application WO2010/022690 discloses the preparation of vildagliptin and purification of the same using various solvents such as acetone, methyl ethyl ketone, cyclohexanone, or mixture of these; toluene, 2-methyl tetrahydrofuran or mixture of these; dimethylcarbonate, ethyl acetate and isopropyl acetate or mixture of these; methanol ethanol, isopropyl alcohol, butanol, and amyl alcohols or mixtures thereof.
  • solvents such as acetone, methyl ethyl ketone, cyclohexanone, or mixture of these; toluene, 2-methyl tetrahydrofuran or mixture of these; dimethylcarbonate, ethyl acetate and isopropyl acetate or mixture of these; methanol ethanol, isopropyl alcohol, butanol, and amyl alcohols or mixtures thereof.
  • PCT application WO2011/101861 A1 reports the novel routes for preparation of vildagliptin, and also discloses the purification of vildagliptin using mixture of ethyl acetate and methanol.
  • Formula (VIII) Formula (IX) International publication number WO 2006/078593 discloses the crystalline form as well as amorphous form of vildagliptin.
  • the patent application discloses amorphous form of vildagliptin and discloses that the amorphous form of vildagliptin was obtained by lypholization from water solution.
  • the patent application does not discuss the amorphous co-precipitates of vildagliptin. Further, the use of lypholization technique for the preparation of the amorphous vildagliptin is not commercially viable.
  • the present invention provides an improved process for the preparation and purification of vildagliptin; wherein the said process substantially eliminates the impurities formed during the preparation and thereby overcomes the above said limitations.
  • the present invention also provides amorphous co-precipitate of vildagliptin or its acid addition salt with a pharmaceutically acceptable excipient and the process for the preparation thereof.
  • the primary object of the present invention is to provide an improved process for the preparation of highly pure vildagliptin.
  • Another object of the present invention is to provide an improved process for the preparation of 1-chloroacetyl-(S)-2-cyanopyrrolidine.
  • Yet another object of the present invention is to provide a process for purification of vildagliptin, wherein the said process substantially eliminates the impurities of formula (IV), formula (VI) and formula (VII), formula (VIII) and formula (IX) formed during the process.
  • Yet another object of the present invention is to provide a process for preparation of vildagliptin of formula (I) wherein the overall yield is improved thereby making the process efficient, high throughput and cost-effective.
  • Yet another object of the present invention is to provide co-precipitate of amorphous vildagliptin or its acid addition salt with a pharmaceutically acceptable excipient and the process for preparation thereof.
  • Figure 1 of the present invention illustrates X-ray powder diffraction (XRD) pattern of co-precipitates of amorphous form of vildagliptin of the formula (I) with povidone as a pharmaceutically acceptable excipient, prepared as per example 16.
  • XRD X-ray powder diffraction
  • Figure 2 of the present invention illustrates an infrared absorption spectrum of co-precipitates of amorphous form of vildagliptin of the formula (I) with povidone as a pharmaceutically acceptable excipient, prepared as per example 16.
  • Figure 3 of the present invention illustrates X-ray powder diffraction (XRD) pattern of co-precipitates of amorphous form of vildagliptin hydrochloride with povidone as a pharmaceutically acceptable excipient, prepared as per example 18. . *
  • Figure 4 of the present invention illustrates an infrared absorption spectrum of co-precipitates of amorphous form of vildagliptin hydrochloride with povidone as a pharmaceutically acceptable excipient, prepared as per example 18.
  • Embodiments of the invention are not mutually exclusive, but may be implemented in various combinations.
  • the described embodiments of the invention and the disclosed examples are given for the purpose of illustration rather than limitation of the invention as set forth the appended claims. Further the terms disclosed embodiments are merely exemplary methods of the invention, which may be embodied in various forms.
  • highly pure vildagliptin or a pharmaceutically acceptable acid addition salt thereof as used herein refers to the vildagliptin or a pharmaceutically acceptable acid addition salt thereof having total purity of greater than about 99%, specifically greater than 99.5%, more specifically greater than about 99.8% and most specifically about 99.99% (measured by HPLC)
  • a term means the herein "reflux temperature" at which the solvent or the solvent system refluxes or boils at atmospheric pressure.
  • coprecipitates or “co-precipitates” as used herein refers to compositions comprising amorphous vildagliptin together with at least one pharmaceutically acceptable excipient, being prepared by removing the solvent from the solution containing both of them.
  • “Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally non-toxic and is not biologically undesirable and includes that which is acceptable for veterinary use and/or human pharmaceutical use
  • excipient means a component of a pharmaceutical product that is not the active ingredient, such as filler, diluents, carrier, and so on.
  • the excipient those are useful in preparing a pharmaceutical composition are generally safe, non-toxic and neither biologically nor otherwise undesirable, and are acceptable for veterinary use as well as human pharmaceutical use.
  • a pharmaceutically acceptable excipient as used in the specification and claims includes both one and more than one such excipient.
  • the present invention provides a process for preparation of vildagliptin of formula (I);
  • vildagliptin of formula (I) b. isolating pure vildagliptin of formula (I).
  • crude vildagliptin of step (a) of the process can be optionally isolated and purified.
  • the solvent used in step (a) is selected from the group comprising of aromatic hydrocarbons such as but not limited to toluene and xylene; aliphatic hydrocarbons such as but not limited to heptanes and hexane; ethers such as but not limited to methyl tertiary butyl ether, di-isopropyl ether, di-ethyl ether and di-methyl ether; cyclic ethers such as but not limited to tetrahydrofuran, and 1 ,4-dioxane; substituted cyclic ethers such as but not limited to 2-methyl tetrahydrofuran and the like; nitriles such as but not limited to acetonitrile, and propionitrile; dialkylformamides, dialkylacetamides; dialkylsulfoxides; halogenated hydrocarbons such as dichloromethane, and dichloroethane; ketones such as
  • the base used in step (a) is either organic or inorganic base.
  • the inorganic base used in step (a) is selected from the group comprising of alkali metal carbonates such as but not limited to potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate; alkali metal hydroxides such as but not limited to sodium hydroxide, potassium hydroxide, magnesium hydroxide, and lithium hydroxide.
  • the organic base used in step (a) is selected from the group comprising of alkyl amines such as but not limited to di-isopropyl ethyl amine, di-isopropyl amine, and triethyl amine; pyridine; or lutidines.
  • step (a) of the reaction is carried out at 10°C to 60°C; preferably at 25°C to 60°C,the reaction mass is cooled and filtered the solid, and the filtrate is concentrated to obtain crude vildagliptin.
  • the obtained crude vildagliptin may be isolated in solid form by treating the crude with methyl ethyl ketone, heating till reflux temperature of the solvent followed by cooling at 0 to 5°C.
  • step (a) is concentrated to obtain crude vildagliptin.
  • the process for isolation of of pure Vildagliptin comprises the steps of:
  • step (i) washing the contents of step (i) with organic solvent
  • the pH of the solution of step (i) is in the range of 1 to 7, preferably in the range of about 4 to 7 using organic or inorganic acid.
  • the organic acid used in step (i) and (v) may be either same or different and the acid is selected from the group comprising of acetic acid, tartaric acid, oxalic acid, fumaric acid, maleic acid, malic acid, glutamic acid, lactic acid, citric acid, salicylic acid, methane sulfonic acid, benzene sulfonic acid, p- toluene sulfonic acid, malonic acid, mandelic acid, succinic acid or mixtures thereof; preferably the said organic acid used is acetic acid or tartaric acid.
  • the inorganic acid used in step (i) is selected from the group comprising of hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid, preferably the acid used is hydrochloric acid.
  • the organic solvent used in step (ii) and (iv) may be either same of different and the organic solvent is selected from the group comprising of aromatic hydrocarbons such as toluene, xylene, and the like; aliphatic hydrocarbons such as hexane, heptanes and the like; halogenated hydrocarbons such as dichloromethane, dichloroethane and the like; carboxylic acid esters such as ethyl acetate, methyl acetate, isopropyl acetate and the like; ethers such as di-ethyl ether, di-isopropyl ether, di-methyl ether, methyl tertiary butyl ether, substituted cyclic ether such as 2-methyl tetrahydrofuran and the like; or mixtures thereof.
  • the solvent used is dichloromethane.
  • the pH of the solution of step (iii) is in the range of 7 to 14, preferably in the range of about 8 to 10 using base; wherein the said base may be organic or inorganic base.
  • the base used is aqueous ammonia.
  • the obtained crude vildagliptin contains less than about 0.2% (2S,2S ')- 1 , 1 '[[3-hydroxytricyclo[3.3.1. .3,7]dec-1 -yl)imino]bis(1 -oxo-2, 1 ,- ethanediyl]bis(2-pyrrolidinecarbonitrile) impurity (Dimer impurity) of formula (VI); 1-aminoadamantane-3-ol impurity of formula (IV) and adamantane-1 ,3- diol impurity (Di-hydroxyl impurity) of formula (VII), deshydroxy impurity of formul
  • Organic solvent used in step (vi) is selected from the group comprising of aliphatic hydrocarbons such as hexane, heptanes and the like; aromatic hydrocarbons such as toluene, xylene and the like; ketones such as acetone, methyl ethyl ketone methyl isobutyl ketone and the like; esters such as ethyl acetate, methyl acetate, isopropyl acetate and the like; nitriles such as acetonitrile, propionitrile and the like; ethers such as di-methyl ether, di-ethyl ether, di-isopropyl ether, methyl tertiary butyl ether and the like; cyclic ethers such as tetrahydrofuran, 2-methyl tetrahydrofuran, 1 ,4-dioxane and the like; alcohols such as methanol, ethanol, isopropyl alcohol and the like
  • the solution obtained in step (vi) may be in suspension or slurry form or in solution form after addition of the said organic solvent.
  • the solution obtained in step (vi) may be partially distilled out under reduced pressure or at atmospheric pressure.
  • step (vi) The solution obtained in step (vi) can be stirred at appropriate temperature over suitable period to recover highly pure vildagliptin by filtration.
  • the obtained highly pure vildagliptin may be further subjected to drying.
  • the drying may be done at atmospheric pressure or reduced pressures, such as below 200 mm/Hg, or below 50 mm/Hg, and at temperature in the range of about 35°C to 80°C.
  • step (3) drying the obtained solid of step (2) to yield pure vildagliptin having less than about 0.2% dimer compound of formula (VI).
  • the suspension obtained in step (1) is prepared using solvent.crude vildagliptin in the ratio of about 1 : 1 to about 1 :15
  • the suspension obtained in step (2) is heated at a temperature of about 25°C to the reflux temperature of the solvent over a period of 30 min to 2 hour.
  • the suspension or clear solution obtained in step (2) containing vildagliptin and solvent may be optionally cooled to obtain slurry before filtration at temperature between 0°C-75°C, particularly between 0°C to 40°C.
  • the slurry obtained may be optionally maintained for a period 30 min to 12 hours, preferably for 2 to 4 hours, at temperature about 0°C to 40°C prior to filtration.
  • the solid obtained after filtration in step (2) may be optionally washed with organic solvent before subjecting the same to drying.
  • Organic solvent used in step (1) for suspension may be either same or different and is selected from the group comprising of aliphatic hydrocarbons such as hexane, heptanes and the like; aromatic hydrocarbons such as toluene, xylene and the like; ketones such as acetone, methyl ethyl ketone methyl isobutyl ketone and the like; esters such as ethyl acetate, methyl acetate, isopropyl acetate and the like; nitriles such as acetonitrile, propionitrile and the like; ethers such as di-methyl ether, di-ethyl ether, di- isopropyl ether, methyl tertiary butyl ether and the like; cyclic ethers such as tetrahydrofuran, 2-methyl tetrahydrofuran, 1 ,4-dioxane and the like; alcohols such as methanol, ethanol, iso
  • the solid is filtered and may be subjected to drying to get pure vildagliptin of formula (I). Drying may be carried out using conventional methods such as Air tray drier (ATD), Vacuum Tray Drier (VTD), Fluidized bed drier (FBD), Spin Flash Drier (SFD), Flash Drier (FD), and the like. Further, the overall yield of vildagliptin of formula (I) obtained using the process of the present invention is at least about 65% with purity of at least about 99% (by HPLC).
  • the total purity of vildagliptin of formula (I) obtained is at least about 99.80% (by HPLC).
  • the present invention provides pure vildagliptin of formula (I) containing less than about 0.2% of impurities namely:
  • the present invention provides a one-pot process for the preparation of 1-chloroacetyl- (S)-2-cyanopyrrolidine, a vildagliptin intermediate; wherein the said process comprises the steps of:
  • step (I) reacting the reaction mass of step (I) with a dehydrating agent optionally in presence of a second base;
  • step (I) of the reaction is carried out at 10° C to 60° C; preferably at 25°C to 60°C, over a period of 2- 12 hours, preferably for about 3-4 hrs.
  • the solvent used in step (I) is selected from the group comprising of aromatic hydrocarbons such as but mot limited to toluene and xylene; aliphatic hydrocarbons such as but not limited to heptanes, and hexane; ethers such as but not limited to methyl tertiary butyl ether, di-isopropyl ether, di-ethyl ether and di-methyl ether; cyclic ethers such as but not limited to tetrahydrofuran; substituted cyclic ethers such as but not limited to 2-methyl tetrahydrofuran and the like; halogenated hydrocarbons such as dichloromethane, and dichloroethane; or mixtures thereof; preferably tetrahydrofuran and/or dichloromethane
  • aromatic hydrocarbons such as but mot limited to toluene and xylene
  • aliphatic hydrocarbons such as but not limited to heptanes, and hexane
  • the first base and second base used in step (I) and (II) respectively is either organic or inorganic base; wherein the first base and second base used in step (I) and (II) can be either same or different.
  • the inorganic base used in step (I) and (II) is selected from the group comprising of alkali metal carbonates such as but not limited to potassium
  • alkali metal hydroxides such as but not limited to sodium hydroxide, potassium hydroxide, magnesium hydroxide, and lithium hydroxide.
  • the organic base used in step (I) and (II) is selected from the group comprising of alkyl amines such as but not limited to di-isopropyl ethyl amine, di-isopropyl amine, and triethyl amine; heterocyclic amines such as but not limited to imidazole pyridine; and lutidines.
  • Dehydrating agent used in step (II) includes but does not limit to trifluoroacetic anhydride, phosphorous oxychloride, thionyl chloride, or phosphorous pentoxide.
  • step (II) of the reaction is carried out at 10° C to 60° C; preferably at 25°C to 60°C over a period of 2- 20 hours, preferably for about 14-15 hrs.
  • acetic acid may be added to obtain the homogenous the reaction mass.
  • Isolation of 1-chloroacetyl-(S)-2-cyanopyrrolidine can be carried out by the process known in skilled art which involves steps such as quenching of reaction mass, washings of aqueous acid, followed by washings of aqueous basic solutions, followed by water washings, distillation, filtration etc.
  • step (III) quenching the reaction mass of step (III) containing 1-chloroacetyl-(S)-2- cyanopyrrolidine with water and ammonium carbonate;
  • step (III) quenching the reaction mass of step (III) containing 1-chloroacetyl-(S)-2- cyanopyrrolidine with water and ammonium carbonate;
  • step (III) quenching the reaction mass of step (III) containing 1-chloroacetyl-(S)-2- cyanopyrrolidine with water and ammonium carbonate;
  • B separating the organic layer, washing with aqueous acid solution, aqueous basic solution and with water
  • step (B) distillating organic layer of step (B) to obtain 1-chloroacetyl-(S)-2- cyanopyrrolidine;
  • step (C) purifying the product of step (C) by crystallization using organic solvent to provide1-chloroacetyl-(S)-2-cyanopyrrolidine.
  • the solvent used in step (D) may be an organic solvent or inorganic solvent or mixture thereof.
  • the solvent comprises of aromatic hydrocarbons such as but not limited to toluene and xylene; aliphatic hydrocarbons such as but not limited to heptanes and hexane; ethers such as but not limited to methyl tertiary butyl ether, di-isopropyl ether, di-ethyl ether and di-methyl ether; cyclic ethers such as but not limited to tetrahydrofuran, and 1 ,4-dioxane; substituted cyclic ethers such as but not limited to 2-methyl tetrahydrofuran and the like; nitriles such as but not limited to acetonitrile, and; halogenated hydrocarbons such as dichloromethane, and dichloroethane; ketones such as acetone or; esters; alcohols such as but not limited to methanol, ethanol, isopropanol, butanol and the like or mixtures thereof.
  • aromatic hydrocarbons
  • a co- precipitate of amorphous form of vildagliptin of the formula (I) or its acid addition salt with a pharmaceutically acceptable excipient characterized by their X-ray diffraction (XRD) pattern and infrared absorption (IR) spectrum.
  • the X-ray diffractogram was measured on Bruker Axe, DS advance Power X-ray Diffractometer with Cu K alpha-1 Radiation source having the wavelength 1.541A° as depicted in figure 1
  • the IR spectrum of amorphous from of vildagliptin hydrochloride with pharmaceutically acceptable excipient having major peaks at 1019.98 cm “1 , 1288.99 cm “1 , 1422.70 cm “1 , 1459.56 cm “ 1 , 1664.16 cm “1 , 2242.90 cm “1 , 2858.17 cm “1 , 2925.24 cm “1 , 3419.94 cm “1 .
  • the IR spectra of co-precipitates of the invention has been recorded on a Fourier Transform Infrared Spectroscopy, Perkin Elmer model 100 instrument using potassium bromide pellet method.
  • the weight ratio of amorphous form of vildagliptin of the formula (I) to the pharmaceutically acceptable excipient is in the range from 10% to 100%; preferably, the weight ratio is in the range from 25% to 50%.
  • the pharmaceutically acceptable excipients which is used in the co- precipitate of invention includes but does not limit to, pharmaceutical hydrophilic carriers such as polyvinylpyrrolidone (homopolymers, also called “povidone”, or copolymers of N-vinylpyrrolidone), gums, cellulose derivatives (including hydroxypropyl methylcellulose, hydroxypropyl cellulose and others), cyclodextrins, gelatins, hypromellose phthalate, sugars, polyhydric alcohols, etc.
  • pharmaceutical hydrophilic carriers such as polyvinylpyrrolidone (homopolymers, also called “povidone”, or copolymers of N-vinylpyrrolidone), gums, cellulose derivatives (including hydroxypropyl methylcellulose, hydroxypropyl cellulose and others), cyclodextrins, gelatins, hypromellose phthalate, sugars, polyhydric alcohols, etc.
  • pharmaceutical hydrophilic carriers such
  • viscosity grades, molecular weight, commercially available products, their copolymers, mixtures are all within the scope of this invention without limitation.
  • the said excipient used in the co-precipitation of vildagliptin is povidone.
  • the co-precipitate according to the invention comprises either amorphous form of vildagliptin of formula (I) or its acid addition salts like hydrochloride, fumarate, tartarate, succinate, methane sulfonate, toluene sulfonate, benzene sulfonate, maleate, malate, lactate, citrate, malonate, mandelate, and the like.
  • step (b) removing the solvent from solution obtained in step (a)to provide amorphous co-precipitate of vildagliptin or its acid addition salts with the pharmaceutically acceptable excipient.
  • the solution prepared in step (a) is filtered to remove insoluble matter; wherein the removal of the said insoluble matter can be done by subjecting the solution of step (a) to filtration, centrifugation, decantation, and other techniques.
  • the solution may be filtered by passing through paper, glass fiber, or other membrane material, or particulate filtration medium such as celite or calcined diatomaceous earth (Hyflo).
  • particulate filtration medium such as celite or calcined diatomaceous earth (Hyflo).
  • the filtration apparatus may need to be preheated to avoid crystallization.
  • the solution of vildagliptin or its acid addition salt and pharmaceutically acceptable excipients prepared in step (a) can be done by any of the following methods:
  • the solvents used for preparing the solution (A) and the solution (B) need not be the same as long as the solvents have mutual solubility and form a single phase.
  • vildagliptin or its acid addition salt should be completely soluble in the solvents used and should provide a clear solution. The presence of un- dissolved crystals could lead to the formation of a material that is not completely amorphous.
  • step (a) may be obtained directly from a reaction in which vildagliptin or its acid addition salts is formed.
  • Vildagliptin or its acid addition salts used to prepare the solution of step (a) is in any form of vildagliptin or its acid addition salts such as crystalline form, solvates and hydrates thereof.
  • the solvent used for the preparation of solution of .step (a) includes; but does not limit to alcohols such as methanol, ethanol, isopropanol, and the like; halogenated hydrocarbons such as dichloromethane, 1 ,2-dichloroethane, chloroform, carbon tetrachloride and the like; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and the like; esters such as ethyl acetate, n-propyl acetate, n-butyl acetate, t-butyl acetate and the like; ethers such as diethyl ether, dimethyl ether, diisopropyl ether and the like; hydrocarbons such as toluene, xylene, n-heptane, cyclohexane, n-hexane and the like; nitriles such as acetonitriles, pro
  • the dissolution temperature to prepare the solution of step (a) is in the range from about 20°C to 120°C or reflux temperature of the solvent/mixture of solvents used for dissolution.
  • the temperature used for dissolution can be of any temperature as long as the solution obtained is a clear solution.
  • the quantity of solvent used for dissolution depends on the kind of solvent and the dissolution temperature adopted to prepare the solution of step (a).
  • the concentration of vildagliptin or its acid addition salt in the solution may range from about 0.1 g/ml to about 10 g/ml in the solvent, and the volume of the solvent may be kept to a minimum so as to facilitate the effective solvent removal.
  • step (b) The removal of solvent in step (b) can be accomplished by filtration, distillation, evaporation, atmospheric distillation, concentration, distillation under vacuum such as rotary evaporator, lyophilization, freeze drying, spray drying, agitated thin film drying (ATFD), or the like.
  • the removal of the solvent from the solution of vildagliptin or its acid addition salts and a pharmaceutical excipient may be affected at increased temperature, preferably at reflux temperature, and/or reduced pressure.
  • the drying of the residue in step (c) is carried out at atmospheric pressure or reduced pressures, such as below about 200 mm/Hg, or below about 50 mm/Hg, at temperatures such as about 35°C to about 70°C.
  • the drying may be carried for any time such as about 1 to 15 hours depending on the product specifications. Temperatures and pressures will be chosen based on volatility of the solvent used in the preparation of solution.
  • the co-precipitate of the invention makes the amorphous form of vildagliptin or its acid addition salt stable and thus they can be handled easily.
  • a process for the preparation of co-precipitate of amorphous form of vildagliptin or its acid addition salts with pharmaceutically acceptable excipients is simple and easy to carry out.
  • amorphous vildagliptin (without excipients) may be obtained using the above described process.
  • the present invention is described with reference to the following examples illustrating the process for preparation and purification of vildagliptin; process for preparation and purification of 1-chloroacetyl-(S)-2-cyanopyrrolidine, and improved and novel process for the preparation of the coprecipitates of amorphous vildagliptin or its acid addition salts.
  • these examples are provided for illustrative purposes only and or not to be construed as limitations on scope of the process of this invention.
  • reaction mass was then quenched drop wise to ice-water mixture (1.6 L) with maintaining the temperature OX to 5°C.
  • 50% aqueous KOH or NaOH solution was added to adjust pH about 13 to 14 (temperature controlled up to 50°C).
  • the aqueous reaction mass was extracted thrice by mixture of n- butanol and toluene at 25°C to 30°C (800 ml butanol and 200 ml toluene).
  • Example-9 Preparation of (2S)-1- ⁇ [(3-hydroxytricyclo[3.3.1.1(3,7)dec-1- yl)amino]-2-pyrrolidine carbonitrile (Crude vildagliptin) To a heterogeneous solution of 3-amino- 1-adamantanol (3.0 g) and tetrahydrofuran (30 ml), potassium carbonate (6.94 g) and Kl (0.15 g) were charged. Resulting reaction mass was then stirred for 10 minutes at 25°C to 30°C.
  • Example- 11 Purification of vildagliptin
  • Example- 12 Purification of vildagliptin
  • Example-13 Preparation of (2S)-1- ⁇ [(3-hydroxytricyclo[3.3.1.1(3,7)dec-1- yl)amino]-2-pyrrolidine carbonitrile (highly pure vildagliptin)
  • Reaction mass was filtered and washed the solid with tetrahydrofuran (100 ml). Filtrate was concentrated under reduced pressure to obtain crude vildagliptin.
  • DM water 600 ml was charged to crude vildagliptin and pH of aqueous solution was adjusted to 5-6 using acetic acid. Aqueous acidic solution was then washed with dichloromethane (4 X 500 ml). Aqueous layer was separated and basified using aqueous ammonia till pH 9-10. Product was extracted from aqueous layer using dichloromethane (4 X 500 ml) and distilled off the organic layer under reduced pressure to obtain crude vildagliptin .
  • Methyl ethyl ketone (200 ml) was added to crude vildagliptin at temperature 25°C to 30°C and distilled under reduced pressure at 40°C to 45°C to obtain crude vildagliptin.
  • Methyl ethyl ketone (175 ml) was charged to the vildagliptin and stirred at 25°C to 30°C. Resulted slurry was cooled at 0°C to 5°C for 30 minutes. Filtered the solid and washed with methyl ethyl ketone (35 ml). The solid was dried at 45°C to 50°C under vacuum.
  • Example 16 Co-precipitate of vildagliptin with providone in a ratio of 1:1 using dichloromethane as a solvent
  • Crystalline vildagliptin (5 g) and providone (5 g) (PVP K30) were dissolved in dichloromethane (200 ml) at temperature of 35°C to 40°C. The solution was filtered in hot condition and the dichloromethane was removed under reduced pressure using buchi rotavapor apparatus to obtain co-precipitate of amorphous vildagliptin with povidone (9.5 g)
  • Example 17 Co-precipitate of vildagliptin with providone in a ratio of 1 :1 using dichloromethane as a solvent
  • Example 18 Co-precipitate of vildagliptin hydrochloride with povidone in a ratio of 1 :1 using dichloromethane as a solvent
  • Example 19 Co-precipitate of vildagliptin hydrochloride with providone in a ratio of 1 :1 using dichloromethane as a solvent
  • Aqueous acidic solution was washed with dichloromethane (3 X 250 ml). Aqueous layer was separated and basified using aqueous ammonia till pH 9-10. Product was extracted from aqueous layer using dichloromethane (3 X 250 ml). DM water (250 ml) was charged to the organic layer and pH was adjusted to 5-6 using tartaric acid. Aqueous layer was washed with MDC (3X250 ml), and aqueous layer was separated, basified with aq.NH 3 to pH 9-10. Product was extracted with MDC (3X250 ml) and organic layer was distilled off atmospherically to obtain vildaglitpin.
  • Ammonium bicarbonate (416 g) was slowly charged to the mass, followed by addition of DM water (500 ml) at temperature below 20°C. The reaction mass was stirred at 25-30°C. Organic layer and aqueous layers were separated and organic layer was washed with aqueous 6% HCI (4 X 400 ml), followed by aqueous NaHCO 3 solution (300 ml) and finally washed with (100 ml) DM water and concentrated under vacuum to get residue. IPA (200 ml) was charged to the residue and reaction mass was heated to 45-50°C, followed by addition of n- heptane (200 ml) and stirred for 30-45 minutes.
  • Aqueous acidic solution was washed with dichloromethane (3 X 250 ml). Aqueous layer was separated and basified using aqueous ammonia till pH 9- 10. Product was extracted from aqueous layer using dichloromethane (400 ml and 2 X 100 ml). DM water (200 ml) was charged into organic layer and pH was adjusted to 5-6 using tartaric acid solution. Reaction mass was stirred and organic layer was separated.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
PCT/IN2013/000296 2012-05-04 2013-05-03 A process for the preparation of vildagliptin and its intermediate thereof WO2013179300A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1383/MUM/2012 2012-05-04
IN1383MU2012 IN2012MU01383A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-05-04 2013-05-03

Publications (2)

Publication Number Publication Date
WO2013179300A2 true WO2013179300A2 (en) 2013-12-05
WO2013179300A3 WO2013179300A3 (en) 2014-08-28

Family

ID=49213010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000296 WO2013179300A2 (en) 2012-05-04 2013-05-03 A process for the preparation of vildagliptin and its intermediate thereof

Country Status (2)

Country Link
IN (1) IN2012MU01383A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013179300A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103724248A (zh) * 2014-01-16 2014-04-16 江苏万特制药有限公司 维格列汀工艺杂质的制备方法
CN103804267A (zh) * 2014-02-21 2014-05-21 张家港威胜生物医药有限公司 一种维达列汀简单环保合成工艺
CN103896819A (zh) * 2014-03-25 2014-07-02 宁波美诺华药业股份有限公司 一种(s)-1-氯乙酰基吡咯烷-2-甲酰胺的制备方法
CN103992257A (zh) * 2014-05-16 2014-08-20 苏州天马精细化学品股份有限公司 一种维格列汀粗品的纯化方法
CN104016895A (zh) * 2014-06-24 2014-09-03 万特制药(海南)有限公司 一种维达列汀氧化杂质的制备方法
CN104262227A (zh) * 2014-09-16 2015-01-07 东北制药集团股份有限公司 一种制备(s)-1-(2-氯乙酰基)吡咯烷-2-甲腈的方法
CN104311467A (zh) * 2014-09-11 2015-01-28 青岛国风药业股份有限公司 管式反应连续制备维格列汀的方法及装置
CN104945299A (zh) * 2015-05-28 2015-09-30 烟台万润药业有限公司 一种维格列汀的高效合成方法
WO2015145467A1 (en) * 2014-03-28 2015-10-01 Laurus Labs Private Limited An improved process for preparing vildagliptin
CN105037234A (zh) * 2015-07-30 2015-11-11 上海医药集团青岛国风药业股份有限公司 一种维格列汀降解杂质的制备方法
CN105085360A (zh) * 2015-09-10 2015-11-25 南京理工大学 一种高纯度维格列汀的制备方法
CN105193752A (zh) * 2015-10-27 2015-12-30 石家庄康贺威药业有限公司 一种维格列汀片剂及其制备方法
CN105439873A (zh) * 2014-08-20 2016-03-30 天津药物研究院 3-羟基-1-金刚烷胺的制备方法
CN106117104A (zh) * 2016-06-17 2016-11-16 东北制药集团股份有限公司 一种维格列汀的制备方法
EP3082801A4 (en) * 2013-12-18 2017-07-26 Harman Finochem Limited An advanced and cost-effective process for preparing highly pure vildagliptin
CN107325010A (zh) * 2017-08-14 2017-11-07 四川众邦制药有限公司 一种金刚烷醇的安全制备方法及装置
CN110117122A (zh) * 2019-06-17 2019-08-13 武汉兴天宇环境股份有限公司 一种羟丙甲生产废水处理方法
WO2022003405A1 (en) 2020-07-03 2022-01-06 Savoi Guilherme One-pot process to obtain a pyrrolidine-2-carbonitrile intermediate compound and industrial scale telescopic process to prepare (2s)-1-[n-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile (vildagliptin) using same

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106699627A (zh) * 2016-12-29 2017-05-24 青岛黄海制药有限责任公司 一种多相复式非连续生产法制备1‑(2‑氯乙酰基)‑2‑(s)‑氰基吡咯烷的方法
WO2021116897A1 (en) * 2019-12-10 2021-06-17 Optimus Drugs (P) Ltd Process for the preparation of vildagliptin

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166063A (en) 1998-12-10 2000-12-26 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
WO2006078593A2 (en) 2005-01-18 2006-07-27 Novartis Ag Direct compression formulation and process
US7375238B2 (en) 2003-04-16 2008-05-20 Novartis Ag Process for the preparation of N-substituted 2-cyanopyrrolidines
WO2010022690A2 (en) 2008-08-26 2010-03-04 Zentiva, K.S. A method of preparation of highly pure vildagliptin
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR064833A1 (es) * 2007-01-10 2009-04-29 Medichem Sa Un procedimiento para la preparacion de vildagliptin
PT2247602E (pt) * 2007-11-30 2013-07-10 Novartis Ag Derivados de adamantil o-glucuronido como inibidores da dipeptidilpeptidase iv para o tratamento de diabetes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166063A (en) 1998-12-10 2000-12-26 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US7375238B2 (en) 2003-04-16 2008-05-20 Novartis Ag Process for the preparation of N-substituted 2-cyanopyrrolidines
WO2006078593A2 (en) 2005-01-18 2006-07-27 Novartis Ag Direct compression formulation and process
WO2010022690A2 (en) 2008-08-26 2010-03-04 Zentiva, K.S. A method of preparation of highly pure vildagliptin
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3082801A4 (en) * 2013-12-18 2017-07-26 Harman Finochem Limited An advanced and cost-effective process for preparing highly pure vildagliptin
CN103724248A (zh) * 2014-01-16 2014-04-16 江苏万特制药有限公司 维格列汀工艺杂质的制备方法
CN103724248B (zh) * 2014-01-16 2018-07-27 万全万特制药江苏有限公司 维格列汀工艺杂质的制备方法
CN103804267A (zh) * 2014-02-21 2014-05-21 张家港威胜生物医药有限公司 一种维达列汀简单环保合成工艺
CN103804267B (zh) * 2014-02-21 2016-06-08 张家港威胜生物医药有限公司 一种维达列汀的合成工艺
WO2015123998A1 (zh) * 2014-02-21 2015-08-27 张家港威胜生物医药有限公司 一种维达列汀的合成方法
CN103896819A (zh) * 2014-03-25 2014-07-02 宁波美诺华药业股份有限公司 一种(s)-1-氯乙酰基吡咯烷-2-甲酰胺的制备方法
CN103896819B (zh) * 2014-03-25 2016-02-24 宁波美诺华药业股份有限公司 一种(s)-1-氯乙酰基吡咯烷-2-甲酰胺的制备方法
WO2015145467A1 (en) * 2014-03-28 2015-10-01 Laurus Labs Private Limited An improved process for preparing vildagliptin
CN103992257A (zh) * 2014-05-16 2014-08-20 苏州天马精细化学品股份有限公司 一种维格列汀粗品的纯化方法
CN103992257B (zh) * 2014-05-16 2016-03-30 苏州天马精细化学品股份有限公司 一种维格列汀粗品的纯化方法
CN104016895A (zh) * 2014-06-24 2014-09-03 万特制药(海南)有限公司 一种维达列汀氧化杂质的制备方法
CN105439873A (zh) * 2014-08-20 2016-03-30 天津药物研究院 3-羟基-1-金刚烷胺的制备方法
CN104311467A (zh) * 2014-09-11 2015-01-28 青岛国风药业股份有限公司 管式反应连续制备维格列汀的方法及装置
CN104262227B (zh) * 2014-09-16 2018-09-18 东北制药集团股份有限公司 一种制备(s)-1-(2-氯乙酰基)吡咯烷-2-甲腈的方法
CN104262227A (zh) * 2014-09-16 2015-01-07 东北制药集团股份有限公司 一种制备(s)-1-(2-氯乙酰基)吡咯烷-2-甲腈的方法
CN104945299B (zh) * 2015-05-28 2017-03-15 烟台万润药业有限公司 一种维格列汀的高效合成方法
CN104945299A (zh) * 2015-05-28 2015-09-30 烟台万润药业有限公司 一种维格列汀的高效合成方法
CN105037234A (zh) * 2015-07-30 2015-11-11 上海医药集团青岛国风药业股份有限公司 一种维格列汀降解杂质的制备方法
CN105085360A (zh) * 2015-09-10 2015-11-25 南京理工大学 一种高纯度维格列汀的制备方法
CN105193752A (zh) * 2015-10-27 2015-12-30 石家庄康贺威药业有限公司 一种维格列汀片剂及其制备方法
CN105193752B (zh) * 2015-10-27 2018-03-30 石家庄康贺威药业有限公司 一种维格列汀片剂及其制备方法
CN106117104A (zh) * 2016-06-17 2016-11-16 东北制药集团股份有限公司 一种维格列汀的制备方法
CN107325010A (zh) * 2017-08-14 2017-11-07 四川众邦制药有限公司 一种金刚烷醇的安全制备方法及装置
CN110117122A (zh) * 2019-06-17 2019-08-13 武汉兴天宇环境股份有限公司 一种羟丙甲生产废水处理方法
WO2022003405A1 (en) 2020-07-03 2022-01-06 Savoi Guilherme One-pot process to obtain a pyrrolidine-2-carbonitrile intermediate compound and industrial scale telescopic process to prepare (2s)-1-[n-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile (vildagliptin) using same

Also Published As

Publication number Publication date
WO2013179300A3 (en) 2014-08-28
IN2012MU01383A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2014-02-28

Similar Documents

Publication Publication Date Title
WO2013179300A2 (en) A process for the preparation of vildagliptin and its intermediate thereof
US8198451B2 (en) Process for the synthesis of moxifloxacin hydrochloride
WO2014192030A2 (en) An improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof
WO2013024492A2 (en) A process for the preparation of asenapine and novel salts thereof
WO2024228133A1 (en) Novel salts of tegoprazan and its polymorphs
WO2017060885A1 (en) An improved process for preparation of atorvastatin or pharmaceutically acceptable salts thereof
WO2017191539A1 (en) Process for the preparation dl-proline co-crystal of dapagliflozin
CA2890961A1 (en) Novel polymorphs of azilsartan medoxomil
US11623933B2 (en) Process for the preparation of sodium (2R,5S,13AR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl) carbamoyl)-2,3,4,5,7,9,13,13A-octahydro-2,5-Methanopyrido[1 ′,2′:4,5]pyrazino[2,1 -b] [1,3] oxazepin-8-olate and its polymorphic form
WO2015049698A2 (en) Process for regorafenib
WO2005090301A1 (en) Crystalline form of atorvastatin hemi calcium
US10300044B2 (en) Polymorphic forms of methyl((1S)-1-(((2S)-2-(5-(4′-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate and salts thereof
CA2942280C (en) An improved process for the preparation of exametazime
CA2808731A1 (en) Crystalline forms of maraviroc phosphate and process for maraviroc amorphous form
WO2017081014A1 (en) Process for the preparation of eltrombopag olamine
KR20230022874A (ko) (2s,5r)-5-(2-클로로페닐)-1-(2'-메톡시-[1,1'-비페닐]-4-카르보닐)피롤리딘-2-카르복실산의 합성
WO2010089753A2 (en) Novel polymorphs of lopinavir
WO2012123963A2 (en) A process for preparation of iloperidone and amorphous co- precipitate of iloperidone with pharmaceutically acceptable excipient
AU2013285078A1 (en) Saxagliptin salts
WO2015001568A2 (en) Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof
WO2015031595A1 (en) A process for preparation of saxagliptin and its hydrochloride salt
WO2012168949A2 (en) A process for preparation of nevirapine
WO2014147641A2 (en) Sitagliptin pterostilbene phosphate salt, process for the preparation and pharmaceutical composition thereof
EP2152697A2 (en) Process for the preparation of alfuzosin and salts thereof
WO2012001357A1 (en) Crystalline form of prulifloxacin and processes for its preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13763309

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13763309

Country of ref document: EP

Kind code of ref document: A2